GeneDx

GeneDx, Inc., founded in 2000 and publicly traded under NASDAQ: WGS, is a commercial-stage genomic diagnostics company. Headquartered in Stamford, Connecticut, with laboratory operations in Gaithersburg, Maryland, GeneDx specializes in advanced genetic testing for rare and inherited disorders. The company leverages one of the world's largest rare disease genomic datasets to power its clinical testing capabilities, supporting healthcare providers and hospitals. Learn about GeneDx's global headquarters for detailed location information.

The company offers a comprehensive suite of genetic testing services, including whole exome sequencing, whole genome sequencing, and targeted gene panels. GeneDx's extensive genomic dataset not only aids in patient diagnosis but also supports critical drug discovery initiatives and health system research. To ensure accessibility, GeneDx provides genetic counseling services and financial assistance programs, aiming to facilitate patient access to essential diagnostic testing. Meet GeneDx's team to understand the expertise driving these advancements.

With a revenue of $442.7 million and an employee range of 1,000-5,000 individuals across 3 locations, GeneDx demonstrates significant operational scale. Its market presence is notable within the Medical Testing & Clinical Laboratories and Healthcare sectors, competing with established entities like Fulgent Genetics, NeoGenomics, and Myriad Genetics. The company's commitment to advancing genomic diagnostics positions it as a key player in personalized medicine and rare disease identification.